

Objectives

- To describe decline in cancer mortality rates
- To describe historical events that impacted cancer outcomes
- To describe impact of Medicare and cancer disparities
- To describe disparities in breast and colorectal cancers and multiple myeloma
- To describe future direction in cancer research






Declining Cancer Mortality


 "Know from whence you came. If you know whence you came, there are absolutely no limitations to where you can go."

James Baldwin













Why the Decline? Prevention (especially tobacco control) Wise early detection (especially colon, breast, cervix) Improvements in cancer treatment Sidney Kimmel Cancer Center at Thomas Jefferson University NCI-designated












Medicare

- U.S. national social health insurance program
- Administered by the U.S. federal government since 1966
 - -Americans aged 65 and older who have worked and paid into the system
 - -Younger people with disabilities
- In 2014, 15.6% of Americans were covered

National Center for Health Statistics, *Health, United States, 2013* Cancer Center at Thomas Jefferson University (Washington D.C.: U.S. Department of Health and Human Services, May 2014).







Reducing Disparities


- Major force for racial desegregation of health care facilities
- Reduced disparities in access to care by vigorous enforcement of the Civil Rights Act, a condition of hospital participation
- Hospitals integrated their medical staffs, waiting rooms, and hospital floors in less than four months
- Between 1961 and 1968, hospitalization rates for whites age 65 and older rose 38 percent, while rates for blacks 65 and older jumped 61 percent
- Disparities in access to hospital services for people of all ages narrowed, with the difference in hospitalization rates between whites and blacks falling from 30 percent in 1961 to 17 percent by 1968



































The NIH Revitalization Act of 1993

"Minorities must be included in Federally sponsored clinical trials."

"In phase III trials, there must be valid subset analysis of the differences among the races."





Disparities in Health

The National Cancer Institute (NCI) defines "cancer health disparities" as:


Adverse differences in cancer incidence, cancer prevalence, cancer mortality, cancer survivorship, and burden of cancer or related health conditions that exist among specific population groups in the United States.


Translated, "disparities in health" is the concept that some populations (however defined) do worse than others.








Populations can be defined or categorized by: Gender Race Ethnicity and Culture Area of geographic origin Socioeconomic Status



















Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients; a single-institution compilation compared with the National Cancer Institute SEER database (Morris et al).


- <u>Results</u>: More AA pts presented with advanced stage (AS) tumors in both databases, and higher histologic grade (p<0.001) and nuclear grade than C pts (p<0.001).
- AA pts had lower ER-positivity (51.9% vs. 63.1%, p<0.001) but significantly higher ki-67 (42.4% vs. 28.7%, p<0.001) and p53 expression (19.4% vs. 13.1%, p<0.05) than C pts with all stages of tumors.
- Basal or "triple-negative" breast cancer phenotype was found to be more common in AA pts as compared with C pts (20.8% vs 10.4%, p<0.0001), associated with higher histologic and nuclear grade (p<0.0001).























Outcomes Among Black Patients With Stage II and III Colon Cancer

Black patients were:

- Younger than whites (58 vs 61 years)
- More likely to be female (55% vs 45 %; P = .001)
- Worse overall survival (HR + 1.22)
- Five-year OS for blacks and whites 68% vs 72.8%
- Worse recurrence-free survival (HR 1.14, P + .0045)

Conclusion: Black patients with resected stage II and stage III colon cancer who were treated with the same therapy as white patients experienced worse overall and recurrence-free survival, but similar recurrence-free interval, compared with white patients.





Yothers et al. J Natl Cancer Inst 2011;103:1498-1506


American College of Gastroenterology 2009


- Screening is recommended in African Americans beginning at age 45 years
- CT colonography every 5 years replaces double contrast barium enema, when patients decline colonoscopy
- Fecal immunochemical testing replaces older guaiac-based fecal occult blood testing
 - Annual Hemoccult Sensa and fecal DNA testing every 3 years are alternative cancer detection tests
- A family history of only small tubular adenomas in first-degree relatives is not considered to increase the risk of CRC
- Individuals with a single first-degree relative with CRC or advanced adenomas diagnosed at age ≥60 years can be screened like averagerisk persons
 Sidney Kimmel Cancer Center


Rex DK, et al. Am J Gastroenterol. 2009;104(3):739-750.


Vitamin D and Racial Disparity in Death From Colorectal Cancer Methods: Serum 25(OH)D levels using NHANES III data Results: Black race (HR, 2.04), no insurance, and a history of CRC, and vitamin D deficiency were statistically significant Conclusion: Vitamin D deficiency contributes to excess African American mortality from CRC.


Fiscella et al. Cancer 2011;117:1061-9
































- The goal of the Cancer Moonshot is to make a decade's worth of progress in five years in the prevention, diagnosis, and treatment of cancer
- "I'm putting Joe in charge of Mission Control"
 President Obama

NIH) NATIONAL CANCER INSTITUTE

59

Blue Ribbon Panel Goals BLUE RIBBON PANEL 2016 And the formal an



Future Directions

- Increase minority provider and patient participation in clinical trials
- Engage patients and communities to participate in strategies
- Design and implement cancer prevention trials applicable to specific populations
- Create a climate that enhances accrual and retention of minority participation
- Expand opportunities for access and participation to underserved populations
- · Define and understand possible biological and molecular differences
- Enhance cultural competence
- Expand collaborations with healthcare providers in underserved populations
- Apply existing cancer control measures
- Institute standard guidelines for diagnosis and treatment
- Maximize supportive care and hospice use





